

Table SIV. Efficacy of intravenous immunoglobulins (IVIg) in 4 half-year (HY) periods during the first 24 months of therapy

Disease (n)	HY 1				HY 2				HY 3				HY 4				HY 1-4	
	Score ^a n (%)				Score ^a n (%)				Score ^a n (%)				Score ^a n (%)				Score	Mean ±SD
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4		
PV (7-10)	4	3	3	0	7	2	1	0	5	1	0	2	4	2	0	1	1.6±0.76	
PnBP (1)	0	1	0	0	1	0	0	0	0	0	1	0	0	0	0	1	2.5	
PF (2-3)	2	1	0	0	3	0	0	0	2	0	0	0	2	0	0	0	1.1±0.14	
BP (1)	0	0	0	1	0	0	1	0	0	1	0	0	0	0	1	0	3.0	
PnBP (1)	1	0	0	0	1	0	0	0	1	0	0	0	1	0	0	0	1.0	
Overall (12-16)	7 (43.8)	5 (31.3)	3 (18.8)	1 (6.3)	12 (75.0)	2 (12.5)	2 (12.5)	(0)	8 (61.5)	2 (15.4)	1 (7.7)	2 (15.4)	7 (58.3)	2 (16.7)	1 (8.3)	2 (16.7)	1.6±0.8	

^aScore: 1 (very good); 2 (good); 3 (satisfactory); 4 (unsatisfactory) (for further information see Material and Methods).

PV: pemphigus vulgaris; PnBP: paraneoplastic pemphigus; PF: pemphigus foliaceus; BP: bullous pemphigoid; PnBP: paraneoplastic bullous pemphigoid.